[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635456":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":40,"collaborators":44,"id":47,"slug":19,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":19,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":23,"whyStopped":19,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"St Vincent's Hospital, Sydney","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"A qualitative approach with semi-structured interviews.","EXPERIMENTAL","Through purposive sampling, we plan to conduct interviews with men from two groups: those with high-risk BCR PCa but no ADT+\u002F-ARPI experience, and men with ADT+\u002F-ARPI experience who have experienced breast-related side effects from this treatment. To inform an understanding of how perception of breast-related symptoms might inform treatment preferences, it is important to understand perspectives regarding the hypothetical risk of side-effects as well as those based on actual experience.",[13],"Other: Semi-structured Interview",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Semi-structured Interview","this t study will use qualitative methods to explore men's views of gynaecomastia from high-risk BCR PCa treatments (Stage 1) to inform attributes and levels for a later DCE to examine patient treatment preferences (Stage 2).",[9],null,[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Kinghorn Cancer Centre","RECRUITING","Sydney","New South Wales","2010","Australia",{"type":29,"coordinates":30},"Point",[31,32],151.20732,-33.86785,{"lat":32,"lon":31},[35],{"name":36,"role":37,"phone":38,"phoneExt":19,"email":39},"Anthony M Joshua, MBBS PhD","CONTACT","+61293555655","svhs.cancerresearch@svha.org.au",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Anthony Joshua, FRACP","Medical Oncologist",[45],{"name":46,"class":6},"University of Technology, Sydney","100635456",false,"NCT07552922","Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1","Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Qualitative Stage","DINGO","Inclusion Criteria:\n\n* Men with high-risk BCR PCa but no ADT+\u002F-ARPI experience.\n* Men with ADT+\u002F-ARPI experience who have experienced breast-related side effects from this treatment.\n\nExclusion Criteria:\n\n• Men receiving psychiatric care as a consequence of their prostate cancer diagnosis or treatment thereof.","MALE","18 Years",{"count":57,"type":58},24,"ESTIMATED","INTERVENTIONAL",[61],"NA","This study aims to explore the perceptions of men with prostate cancer (PCa) and high-risk biochemical recurrence (BCR) regarding the risk of breast-related side effects, including gynaecomastia, from treatment.",[64],"Prostate Cancer (Adenocarcinoma)",[66,67,68,69,70,71],"gynaecomastia","prostate cancer","LHRH","testosterone","breast","estrogen","2026-04-22",{"date":74,"type":75},"2026-04-27","ACTUAL",{"date":77,"type":75},"2025-12-01",{"date":79,"type":58},"2026-11-30",{"name":5,"class":6},1]